1030 Massachusetts Avenue
Cambridge, MA 02138
About Werewolf Therapeutics
Werewolf Therapeutics, Inc. is an oncology biotherapeutics company unleashing the power of proinflammatory immune modulators to develop next-generation, transformative cancer therapeutics. The company is advancing a pipeline of treatments designed to focus the body’s immune response to selectively target cancer.
Under precise conditions, Werewolf’s technology allows it to zero in on tumors using validated mechanisms that are known cancer killers, while preventing unwanted side effects on non-target tissues – ultimately delivering a more clinically meaningful impact for patients.
Werewolf’s proprietary PREDATOR™ protein engineering platform combines a variety of approaches to actively silence the drug while in systemic circulation, optimize its pharmacokinetic profile, and rapidly and efficiently transform into the fully active state upon reaching the tumor microenvironment for maximum therapeutic potential.
Werewolf is creating a new era of tumor-selective, systemically delivered drugs with the potential to deliver more effective, less toxic treatments for people with cancer, with the goal of vastly improving their lives.
4 articles with Werewolf Therapeutics
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Financing accelerates Werewolf's pipeline of systemically delivered, conditionally activated INDUKINE™ molecules into clinical stage development and supports efforts to build a leading immuno-oncology drug discovery and development team
This week multiple companies have announced millions of investment dollars have flooded their coffers to advance research and development of multiple therapies. BioSpace is rounding up the announcements.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Expansion of leadership team with deep translational oncology drug development expertise as Company prepares for clinical development of lead programs